Solana Company Q2 FY2022 Earnings Call

· Earnings call transcript and AI-powered summary

Business and Operational Highlights
  • First Commercial Sales of PoNS in the U.S.: Marked the first quarter of commercial sales for the PoNS (Portable Neuromodulation Stimulator) device in the U.S., indicated for the short-term treatment of gait deficit due to mild to moderate MS symptoms.
  • Growing Market Interest: Over 300 inquiries received for the PoNS device, with active follow-up and conversion efforts underway.
  • Therapist Training Improvements: Transitioned from in-person, multi-day training to a self-paced, 3-hour online module, increasing accessibility and enrollment. Over 80 physical therapists are trained or currently registering.
  • Upcoming Telehealth Rollout: A comprehensive online platform, including telehealth, e-commerce, and an online pharmacy, is set to launch later this year, aiming to streamline access and prescription fulfillment in all 50 U.S. states.
  • List Pricing and Patient Access: U.S. list price of PoNS is $25,700 (controller: $17,800; mouthpiece: $7,900). The Patient Therapy Access Program allows patients access at a reduced cost through December 31, 2022.

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Good day and thank you for standing by. Welcome to the Helius Medical Technologies’ Q2 2022 Earnings Conference Call. Today’s conference is being recorded. I would now like to hand the conference over to your speaker today, Lisa Wilson. Please go ahead. Lisa Wilson: Thank you, operator. Welcome to the second quarter 2022 earnings conference call for Helius Medical Technologies. This is Lisa Wilson of In-Site Communications, Investor Relations for Helius. With me on today's call are Dane Andreeff, Helius Medical's President and Chief Executive Officer; and Jeff Mathiesen, Chief Financial Officer. At this time, all participants have been placed in a listen-only mode. Please note that this call is being recorded and access to the webcast can be obtained through the Investors section of the Helius website at heliusmedical.com. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management. These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including those identified in the Risk Factors section of our most recent annual report on Form 10-K and quarterly report on Form 10-Q. Such factors may be updated from time to time in our other filings with the SEC which are available on our website. All statements made during this call are as of A

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional